SRTS

Over the past six months, Sensus Healthcare's stock price has been impacted by several events. The company reported missed consensus estimates for both Q1 2026 and Q4 2025 financial results, with the absence of sales from its largest customer affecting the Q4 results. In March 2026, Sensus Healthcare filed a lawsuit against SkinCure Oncology for breach of contract. The company introduced "Sensus Link" and launched "Sensus Healthcare Financial Services" in February 2026. Dedicated CPT codes for SRT to treat non-melanoma skin cancer were established, effective January 1, 2026. Insider buying activity has been noted. The share price experienced a decline of 17.31% between April 28, 2025, and April 24, 2026, and has traded between $2.82 and $5.92 over the past 52 weeks.